Omega Funds and TCGX led a $207.5m Series C round in Aviceda Therapeutics.

Omega Funds, an international life sciences investment firm, and TCGX, a science-driven investment firm, led a $207.5m Series C round in Aviceda Therapeutics, a private, clinical-stage biotechnology company, with participation from Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management and Digitalis Ventures. “We are proud to support Aviceda and its team of retinal specialists, whose blend of ophthalmic expertise and operational excellence drives Aviceda’s advancement of AVD-104 toward critical milestones,” Bernard Davitian, Omega Funds Partner.